IGF-1R inhibition has received abundant attention over the last decade for multiple cancer types, with the first FDA IGF-1R inhibitor, teprotumumab, a monoclonal antibody indicated for autoimmune Graves’ orbitopathy [156], approved in 2022. The gene discussed is IGF1R; the disease is cancer.